


Dexloxiglumide

Chemical Properties

| | |
|-------------------|---|
| CAS No. : | 119817-90-2 |
| Formula: | C ₂₁ H ₃₀ Cl ₂ N ₂ O ₅ |
| Molecular Weight: | 461.38 |
| Appearance: | no data available |
| Storage: | Powder: -20°C for 3 years In solvent: -80°C for 1 year |



Biological Description

| | |
|---------------|--|
| Description | Dexloxiglumide, an active enantiomer of Loxiglumide, inhibits smooth muscle cell contractions induced by cholecystokinin-octapeptide (CCK-8). It is a selective antagonist of cholecystokinin type A (CCKA) receptors. |
| Targets(IC50) | Others |

Solubility Information

| | |
|------------|---|
| Solubility | DMSO: 50 mg/mL (108.37 mM), Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|-----------|------------|------------|
| 1 mM | 2.1674 mL | 10.8371 mL | 21.6741 mL |
| 5 mM | 0.4335 mL | 2.1674 mL | 4.3348 mL |
| 10 mM | 0.2167 mL | 1.0837 mL | 2.1674 mL |
| 50 mM | 0.0433 mL | 0.2167 mL | 0.4335 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Reference

Scarpignato C, et al. Effect of dexloxiglumide and spiroglumide, two new CCK-receptor antagonists, on gastric emptying and secretion in the rat: evaluation of their receptor selectivity in vivo. Aliment Pharmacol Ther. 1996 Jun;10(3):411-9.

Maselli MA, et al. CCK1 receptor antagonist, dexloxiglumide: effects on human isolated gallbladder. Potential clinical applications. Minerva Gastroenterol Dietol. 2003 Sep;49(3):211-6.

Inhibitor · Natural Compounds · Compound Libraries · Recombinant Proteins

This product is for Research Use Only. Not for Human or Veterinary or Therapeutic Use

Tel: 781-999-4286 E_mail: info@targetmol.com Address: 36 Washington Street, Wellesley Hills, MA 02481